Biotechnology Consulting Poland applies to the EU for structural and cohesion funding

Pulmo BioTech Inc. (OTCBB: PLMO) (FRANKFURT: PBO).

In the same way that the European Union has previously made major infrastructure investments in countries such as Ireland, the EU is now encouraging and funding the development of high tech companies in Poland through its Structural and Cohesion Funds.

Biotechnology Consulting Poland intends to take advantage of this program and has filed its application with the EU for such structural and cohesion funding with an expected response in early 2010.

The advantages to both companies of the letter of intent to bring Pulmo BioTech's Pulmonary Vascular diagnostic technology PulmoBind™ to the EU are that Pulmo BioTech gets access to the European market without having to fund the clinical trials necessary for approval, while Biotechnology Consulting Poland gains access to the innovative PulmoBind™ technology of Pulmo BioTech Inc. -- Garry McCann, CEO Pulmo BioTech Inc.